Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies. Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, MRTX1133 has been shown to confer robust short-term responses in genetically engineered mouse models (GEMM) of PDAC (33) and displayed increased efficacy when combined with immune checkpoint blockade (32).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [33]
In the citing paper
“Consistent with prior reports (32, 33), short-term treatment with MRTX1133 resulted in increases in CD4+ and CD8+ T cells in this orthotopic model (Supplementary Fig. S9A–S9C).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [33]
In the citing paper
“This compound was shown to be most effective in inhibiting tumor activity in patient- and cell line-derived pancreatic G12D xenografts over xenografts from colorectal cancers and other tissues [57].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [57]
In the citing paper
“Recent work has also shown that KRASG12D inhibition leads to an immunogenic response (32, 33); thus, therapies that activate the immune response should be further investigated in combination with KRAS inhibitors in preclinical models and ultimately clinical trials (32, 70).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [33]
In the citing paper
“Preclinical studies demonstrated potent suppression of KRAS G12D signaling and marked antitumor activity in pancreatic and colorectal cancer models [51,53].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [51]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170 · cited 4×
“The PDAC TME is composed of a dense fibrotic stroma (24, 33).”
InfluentialFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“In concordance with our work, recent reports examining the role of Kras G12C inhibitors on the tumor immune microenvironment also identified an increase in M1-like macrophages, a loss of MDSCs, and dependency on a functional immune system (14, 47).”
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“The PDAC TME is composed of a dense fibrotic stroma (24, 33).”
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136 · cited 2×
“To determine the efficacy of MRTX1133 in an autochtho-nous setting, we utilized the stochastic KPC/Y PDAC mouse model (22, 23).”
Self-citationStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085 · cited 3×
“As α SMA + fibroblasts restrain tumor growth in PDAC (35–37), an increase in this CAF subpopulation may also contribute to the antitumor effects of the drug.”
Self-citationOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Self-citationBiffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360 · cited 2×
“As α SMA + fibroblasts restrain tumor growth in PDAC (35–37), an increase in this CAF subpopulation may also contribute to the antitumor effects of the drug.”
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationRoyal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Self-citationRAS-targeted therapies: is the undruggable drugged?
Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · cited 1×
“As more than 90% of patients with PDAC harbor oncogenic mutations in the Kirsten Ras ( KRAS ) oncogene (7), the KRAS oncoprotein stands out as a particularly attractive target for novel PDAC therapy (8).”
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 13×
“Next, we examined the effects of MRTX1133 on the TME in the autochthonous KPC/Y model.”
InfluentialSelf-citationKRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
Waters, A. M., & Der, C. J. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031435 · Cited by 875
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59227 · Cited by 770 · cited 3×
“9–13 ).”
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01688 · Cited by 769 · cited 5×
“25, 26].”
InfluentialSelf-citationDiscovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
Li, J., Byrne, K. T., Yan, F., Yamazoe, T., Chen, Z., Baslan, T., Richman, L. P., Lin, J. H., Sun, Y. H., Rech, A. J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.06.006 · Cited by 750 · cited 1×
“To further test the reproducibility of these effects, we used a third syngeneic Kras G12D PDAC cell clone, 2838c3, which gives rise to T-cell–inflamed tumors that are responsive to combination immunotherapy (30).”
Self-citationSanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 613 · cited 1×
“CCL2 is known to recruit CCR2 + macrophages in PDAC (40).”
Corbett, T. H., Griswold, D. P., Roberts, B. J., Peckham, J. C., & Schabel, F. M. (1975) · PubMed · Cited by 584
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Self-citationNeoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
Leidner, R., Sanjuan Silva, N., Huang, H., Sprott, D., Zheng, C., Shih, Y.-P., Leung, A., Payne, R., Sutcliffe, K., Cramer, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119662 · Cited by 517
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Self-citationWinograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459 · cited 1×
“In our 10 years of experience testing multiple compounds for antitumor effects in this autochthonous model (37, 42–46), the frequency and depth of tumor regressions observed with MRTX1133 are the most prominent yet observed for any compound or compounds.”
Self-citationOrthotopic Models are Necessary to Predict Therapy of Transplantable Tumors in Mice
Killion, J. J., Radinsky, R., & Fidler, I. J. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006140513233 · Cited by 430 · cited 1×
“The efficacy of antitumor agents can vary depending on the tumor site (31).”
Crystal structure of human KRAS G12C covalently bound to a phthalazine inhibitor: 6pgo
Mohr, C. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6pgo/pdb · Cited by 314
Translational advances in pancreatic ductal adenocarcinoma therapy
Hosein, A. N., Dougan, S. K., Aguirre, A. J., & Maitra, A. (2022) · Nature Cancer · doi:10.1038/s43018-022-00349-2 · Cited by 250 · cited 1×
“As more than 90% of patients with PDAC harbor oncogenic mutations in the Kirsten Ras ( KRAS ) oncogene (7), the KRAS oncoprotein stands out as a particularly attractive target for novel PDAC therapy (8).”
Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture
Bertram, J. S., & Janik, P. (1980) · Cancer Letters · doi:10.1016/0304-3835(80)90130-5 · Cited by 216 · cited 2×
“27; Supplementary Fig.”
The Pancreatic Cancer Microenvironment
Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 187
Metastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178 · cited 1×
“These findings are consistent with studies utilizing the inducible iKras genetic mouse model (9, 10, 12), in which Kras G12D deinduction resulted in a rapid loss of p-ERK1/2 expression, increased apoptosis, and tumor regressions within 1 week (9, 10, 12).”
Tumor cell–intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2)
Markosyan, N., Li, J., Sun, Y. H., Richman, L. P., Lin, J. H., Yan, F., Quinones, L., Sela, Y., Yamazoe, T., Gordon, N., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127755 · Cited by 170
Self-citationBriere, D. M., Li, S., Calinisan, A., Sudhakar, N., Aranda, R., Hargis, L., Peng, D. H., Deng, J., Engstrom, L. D., Hallin, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0462 · Cited by 168
Self-citationVander Velde, R., Yoon, N., Marusyk, V., Durmaz, A., Dhawan, A., Miroshnychenko, D., Lozano-Peral, D., Desai, B., Balynska, O., Poleszhuk, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16212-w · Cited by 138 · cited 1×
“Because acquired resistance is a near-universal feature of targeted therapies (48, 49), including KRAS G12C inhibition (50), we estimated the durability of MRTX1133-induced tumor regressions.”
Metastatic progression is associated with dynamic changes in the local microenvironment
Aiello, N. M., Bajor, D. L., Norgard, R. J., Sahmoud, A., Bhagwat, N., Pham, M. N., Cornish, T. C., Iacobuzio-Donahue, C. A., Vonderheide, R. H., & Stanger, B. Z. (2016) · Nature Communications · doi:10.1038/ncomms12819 · Cited by 136
Self-citationRadiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer
Rech, A. J., Dada, H., Kotzin, J. J., Henao-Mejia, J., Minn, A. J., Twyman-Saint Victor, C., & Vonderheide, R. H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3821 · Cited by 115 · cited 1×
“In contrast to the mostly modest antitumor effects that have been previously reported for other compounds in this model, including our own work with immunotherapies (24, 45), the current study produced deep ( > 50”
Self-citationBear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113 · cited 1×
“These approaches will complement other strategies that leverage the ability of Kras G12D to serve as a neoantigen using engineered autologous T cells (51, 52).”
Self-citationExtrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming
Velez-Delgado, A., Donahue, K. L., Brown, K. L., Du, W., Irizarry-Negron, V., Menjivar, R. E., Lasse Opsahl, E. L., Steele, N. G., The, S., Lazarus, J., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.016 · Cited by 91 · cited 4×
“Our findings contrast with those observed in the genetic iKras model, in which Kras G12D deinduction led to a loss of α SMA + fibroblasts (9–11).”
InfluentialSelf-citationThe vascular landscape of human cancer
Kahn, B. M., Lucas, A., Alur, R. G., Wengyn, M. D., Schwartz, G. W., Li, J., Sun, K., Maurer, H. C., Olive, K. P., Faryabi, R. B., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci136655 · Cited by 54 · cited 1×
“Although a small percentage of patients with PDAC exhibit hypervascular tumors, the majority of PDAC tumors are hypovascular (24, 38).”
Self-citationEpithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice
Zhang, Y., Yan, W., Mathew, E., Kane, K. T., Brannon, A., Adoumie, M., Vinta, A., Crawford, H. C., & Pasca di Magliano, M. (2017) · eLife · doi:10.7554/elife.27388 · Cited by 52 · cited 4×
“9–13 ).”
InfluentialUltrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Hay, C., Sor, R., Flowers, A., Clendenin, C., & Byrne, K. T. (2019) · Journal of Visualized Experiments · doi:10.3791/60497 · Cited by 13 · cited 2×
“For orthotopic injections, 6.25 × 10 4 tumor cells were implanted directly into the pancreas as previously described (32).”
InfluentialSelf-citationUltrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma
Hay, C. A., Sor, R., Flowers, A. J., Clendenin, C. J., & Byrne, K. T. (2019) · Journal of Visualized Experiments · doi:10.3791/60497-v · Cited by 5
Self-citation
Cited by
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
“MRTX1133 induced tumour regression, reduced tumour-infiltrating myeloid-derived suppressor cells (MDSCs), increased M1-like macrophages and expanded the number of tumour-infiltrating cytotoxic T cells in preclinical Kras G12D mouse tumour models 105,106 .”
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“https://doi.org/10.1038/s41591-024-02903-0 effectors of KRAS in vitro and leads to robust tumor regression in human patient-derived xenografts of NSCLC, PDAC and CRC and in mouse models 56,65,67,68 .”
InfluentialTranslational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Dilly, J., Hoffman, M. T., Abbassi, L., Li, Z., Paradiso, F., Parent, B. D., Hennessey, C. J., Jordan, A. C., Morgado, M., Dasgupta, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0177 · Cited by 308
“Moreover, MRTX1133 has been shown to confer robust short-term responses in genetically engineered mouse models (GEMM) of PDAC (33) and displayed increased efficacy when combined with immune checkpoint blockade (32).”
BackgroundResultSelf-citation
Metadata
- Authors
- Kemp, S. B., Cheng, N., Markosyan, N., Sor, R., Kim, I.-K., Hallin, J., Shoush, J., Quinones, L., Brown, N. V., Bassett, J. B., Joshi, N., Yuan, S., Smith, M., Vostrejs, W. P., Perez-Vale, K. Z., Kahn, B., Mo, F., Donahue, T. R., Radu, C. G., Clendenin, C., Christensen, J. G., Vonderheide, R. H., & Stanger, B. Z.
- Affiliations
- Abramson Cancer Center (US)
- Mirati Therapeutics (United States) (US)
- University of California, Los Angeles (US)
- Corresponding author
- Vonderheide, Robert H.
- Stanger, Ben Z.
- ORCID
- Kemp, Samantha B.
- Cheng, Noah
- Markosyan, Nune
- Sor, Rina
- Kim, Il-Kyu
- Hallin, Jill
- Shoush, Jason
- Quinones, Liz
- Brown, Natalie V.
- Bassett, Jared B.
- Joshi, Nikhil
- Yuan, Salina
- Smith, Molly
- Vostrejs, William P.
- Perez-Vale, Kia Z.
- Kahn, Benjamin
- Mo, Feiyan
- Donahue, Timothy R.
- Radu, Caius G.
- Clendenin, Cynthia
- Christensen, James G.
- Vonderheide, Robert H.
- Stanger, Ben Z.
- Venue
- Cancer Discovery
- Published
- 2022-12-06
- Volume
- 13
- Issue
- 2
- Pages
- 298-311
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC9900321
- OpenAlex
- W4310780368
- Cited by
- 370
- References
- 54
- Citations by year
- 2026: 72 · 2025: 111 · 2024: 111 · 2023: 76
- FWCI
- 31.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
- Funders
- National Cancer Institute (CA229803, CA252225, CA009140, CA016520)
- Cancer Research Institute (CRI4097)
- Parker Institute for Cancer Immunotherapy
- Abramson Family Cancer Research Institute
- Penn Pancreatic Cancer Research Center
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS G12D, MRTX1133, KRAS inhibitors, pancreatic ductal adenocarcinoma, tumor microenvironment, tumor-associated macrophages, tumor fibroblasts, T cell dependence, tumor regression, tumor cell apoptosis
- MeSH terms
- Heterocyclic Compounds, 2-Ring, Humans, Mutation, Naphthalenes, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Cell Line, Tumor, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.